Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INSULET CORPORATION

(PODD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Insulet to Present at Nasdaq's 45th Investor Conference

11/25/2021 | 08:36am EST

ACTON, Mass. - Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod brand of products, announced that management will present at the virtual 45th Nasdaq Investor Conference on Friday, December 3, 2021 at 11:30 a.m. (Eastern Time).

To listen to the live webcast of the presentation, please visit investors.insulet.com/events. A replay of the webcast will also be available following the event.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.

Contact:

Investor

Deborah R. Gordon

Vice President

Investor Relations

T: (978) 600-7717

E: dgordon@insulet.com

Merrill Robichaud

Investor Relations Coordinator

T: (978) 932-0444

E: mrobichaud@insulet.com

Media

Angela Geryak Wiczek

Senior Director

Corporate Communications

T: (978) 932-0611

E: awiczek@insulet.com

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about INSULET CORPORATION
01/12CORRECTING and REPLACING Insulet to Announce Fourth Quarter and Full Year 2021 Financia..
BU
2021Berenberg Bank Terminates Coverage on a Number of Companies Due to Analysts' Departures..
MT
2021Insulet to Present at Nasdaq's 45th Investor Conference
AQ
2021Insulet to Present at Nasdaq's 45th Investor Conference
BU
2021INSIDER SELL : Insulet
MT
2021Raymond James Adjusts Price Target on Insulet to $329 from $285, Keeps Outperform Ratin..
MT
2021UBS Lifts Insulet's Price Target to $325 From $267 on Sales Estimates; Neutral Rating K..
MT
2021Berenberg Bank Adjusts Insulet's Price Target to $295 From $277, Maintains Hold Rating
MT
2021SVB Leerink Adjusts Price Target on Insulet to $350 from $300, Keeps Outperform Rating
MT
2021INSULET CORP Management's Discussion and Analysis of Financial Condition and Results o..
AQ
More news
Analyst Recommendations on INSULET CORPORATION
More recommendations
Financials (USD)
Sales 2021 1 091 M - -
Net income 2021 13,4 M - -
Net Debt 2021 333 M - -
P/E ratio 2021 1 148x
Yield 2021 -
Capitalization 16 022 M 16 022 M -
EV / Sales 2021 15,0x
EV / Sales 2022 12,7x
Nbr of Employees 1 900
Free-Float 99,5%
Chart INSULET CORPORATION
Duration : Period :
Insulet Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INSULET CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 232,32 $
Average target price 309,94 $
Spread / Average Target 33,4%
EPS Revisions
Managers and Directors
Shacey Petrovic President, Chief Executive Officer & Director
Wayde Dwight McMillan Chief Financial Officer, Treasurer & Executive VP
Timothy J. Scannell Independent Chairman
Trang Ly Senior Vice President & Medical Director
Charles Alpuche Chief Operations Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
INSULET CORPORATION-12.68%16 022
ABBOTT LABORATORIES-11.39%213 874
MEDTRONIC PLC2.57%142 671
BECTON, DICKINSON AND COMPANY4.93%75 243
HOYA CORPORATION-10.96%49 292
BAXTER INTERNATIONAL INC.0.17%43 055